Shankman Michael Elliot 4
4 · Lexaria Bioscience Corp. · Filed May 16, 2025
Insider Transaction Report
Form 4
Shankman Michael Elliot
Chief Financial Officer
Transactions
- Award
Stock Options
2025-05-15+50,000→ 100,000 totalExercise: $1.04From: 2025-05-15Exp: 2030-05-15→ Common Shares (50,000 underlying)
Holdings
- 50,000
Stock Options
Exercise: $3.17From: 2025-02-28Exp: 2029-10-01→ Common Shares (50,000 underlying)
Footnotes (1)
- [F1]20,000 options are exercisable as of February 28, 2025, an additional 15,000 options are exercisable on August 31, 2025 and the remaining 15,000 options are exercisable on August 31, 2026